Search results for " Long-term follow-up"

showing 4 items of 4 documents

Persistence of Nonceliac Wheat Sensitivity, Based on Long-term Follow-up

2017

We investigated how many patients with a diagnosis of nonceliac wheat sensitivity (NCWS) still experienced wheat sensitivity after a median follow-up time of 99 months. We collected data from 200 participants from a previous study of NCWS, performed between July and December 2016 in Italy; 148 of these individuals were still on a strict wheat- free diet. In total, 175 patients (88%) improved (had fewer symptoms) after a diagnosis of NCWS; 145 of 148 patients who adhered strictly to a gluten-free diet (98%) had reduced symptoms, compared with 30 of 52 patients who did not adhere to a gluten-free diet (58%) (P < .0001). Of the 22 patients who repeated the double-blind, placebo- controlled …

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaLong term follow upNonceliac Wheat SensitivityWheat HypersensitivityPersistence (computer science)PersistenceDiet Gluten-Free03 medical and health sciences0302 clinical medicineFood allergySurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesIrritable bowel syndromeHepatologyLong-term Follow-upbusiness.industryGastroenterologyMiddle Agedmedicine.disease030220 oncology & carcinogenesisChronic DiseasePatient CompliancePersistence; Nonceliac Wheat Sensitivity; Long-term Follow-upFemale030211 gastroenterology & hepatologySymptom AssessmentbusinessFollow-Up Studies
researchProduct

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct

Congenital diaphragmatic hernia and esophageal atresia: The importance of respiratory follow-up in congenital thoracic malformations

2013

Esophageal atresia, congenital diaphragmatic hernia, pulmonary function test, respiratory morbidity, Long-term follow-up

Settore MED/38 - Pediatria Generale E SpecialisticaEsophageal atresia congenital diaphragmatic hernia pulmonary function test respiratory morbidity Long-term follow-up
researchProduct

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalen…

2020

Abstract Background We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. Methods This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12–22 months from 10 European countries were randomized in a 3:3:1 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose of V (MMR + V group), or two doses of MMR (MMR; control group), 42 days apart. Vaccine efficacy (VE) against varicella (confirme…

Slovakiamedicine.medical_specialtyVaricella vaccineAntibodies Viralmedicine.disease_causelaw.inventionChickenpox Vaccine03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030225 pediatricsInternal medicineEpidemiologymedicineHumansVaccines Combined030212 general & internal medicineChildAdverse effectMumpsRubellaCzech RepublicGeneral VeterinaryGeneral Immunology and MicrobiologyRomaniabusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthVaricella zoster virusInfantVaccine efficacyConfidence intervalEuropeInfectious DiseasesMolecular MedicinePolandbusinesschildren ; efficacy ; live-attenuated varicella vaccine ; long-term follow-up ; measles-mumps-rubella ; varicella zoster virusMeasles-Mumps-Rubella VaccineFollow-Up StudiesMeaslesVaccine
researchProduct